To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 369 participants.

Also called NCT05852431

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 369 participants (enrolled count) (from the registry)
Sponsor
89bio, Inc. (from the registry)
Registry
  • NCT NCT05852431
  • EU CT 2023-503576-25-00
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Austria, Belgium, Bulgaria, Canada, Chile, Czechia, France, Georgia, Germany, Hungary, India, Italy, Latvia, Mexico, Poland, Puerto Rico, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05852431. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-15 (actual); primary completion 2025-07-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
Acronym
ENTRUST
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
Pegozafermin
Intervention (Drug)
Placebo
Lead sponsor
89bio, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05852431
Content hash
0e09e6f365423cf33e4f47ed4d4f8efaec7cbe28c756d8ca26b843bba43de3c1